KNP_Logo_Homepage Fachartikel

Stand: 18. 08. 2008

-> Literaturempfehlungen   -> Videos   -> Links   -> Datenschutz

 

Fachartikel

 

Allert N, Volkmann J, Dotse S, Hefter H, Sturm V and Freund H-J. Effects of bilateral pallidal or subthalamic stimulation on gait in advanced Parkinson's disease. Mov disord 2001; 16:1076-85

Althaus A, Kanis T, Spottke A, Eggert K, Liepelt I, Berg D, Schneider F, Dodel R. Benchmarking in der Patientenversorgung. Nervenheilkunde 2007; 26: 277-280

Alvarez-Fischer D, Blessmann G, Trosowski C, Béhé M Schurrat T, Hartmann A, Oertel WH, Höglinger GU, Höffken H. Quantitative I-FP-CIT Pinhole SPECT Imaging predicts Striatal Dopamine Levels, but not number of nigral Neurons in different mouse models of Parkinson’s disease. Neuroimage 2007

Anagnostou E, Sporer B, Steude U, Kempermann U, Büttner U, Bötzel K: Contraversive eye deviation during deep brain stimulation of the globus pallidus internus. Neurology 2001; 56:1396-1399

Antony G, Eggert K, Franke S, Oertel W. Die elektronische Kommunikationsstruktur des Kompetenznetzes Parkinson. Der Kassenarzt 2006; 4:351-352

Antony G, Eggert K, Franke S, Oertel WH. Die elektronische Kommunikationsstruktur des Kompetenznetzes Parkinson. Telemedizinführer Deutschland Ausgabe 2006, Hrsg. Achim Jäckel, 7. Auflage

Antony G, Eggert K, Franke S, Oertel WH. Das Patientenregister. Nervenheilkunde 2007; 26: 241-245

Apomorphine therapy versus deep brain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease. Nervenarzt 2001; 72(12):924-7

Baas H. Pharmakotherapie und Leitlinien: Das Parkinson-Syndrom. Pharmazie in unserer Zeit 2006; 35:242-248

Baas H, Jost W. Parkinson-Kongress wird zur festen Größe: Standort Deutschland stärken. MedReport 2005; Nr. 3

Baum E, Heinermann A, Donner-Banzhoff N, Oertel WH: Detecting Parkinson's Disease in a network setting. Family Practice 2000; Vol. 17: 21

Baum E, Höglinger GU, Rissling I, Ries V, Donner-Banzhoff N, Oertel WH. Evaluation von Screeninginstrumenten in der Allgemeinarztpraxis zur Früherkennung des Morbus Parkinson. 35. Kongress der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin. 20.-22. September 2001, Hannover

Baum E, Rissling I, Metz A, Ries V, Donner-Banzhoff N, Oertel WH. Praxistest eines Stufen-Screenings auf M. Parkinson. Zeitung für Allgemeinmedizin. 2002; 78:17

Becker A, Eggert K, Moeller JC, Oertel WH. Was gibt es Neues in der Therapie der Parkinson-Krankheit? 14. Frankfurter Parkinson-Symposium 2004, Editiones Roche, Roche Interaktiv; 139-149

Becker G, Berg D, Lesch KP, Becker T. Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings, Int J Neuropsychopharmacol 2001; 4:21-31

Benamer HTS, Oertel WH, Patterson J, Hadley DM, Pogarell O, Höffken H, Gerstner A, Grosset DG. Prospective Study of Presynaptic Dopaminergic Imaging in Patients With Mild Parkinsonism and Tremor Disorders: Part 1. Baseline and 3-Month Observations. Mov Disord 2003, Vol. 18, No. 9: 977-984

Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000 May;15(3):503-10.

Bereznai B, Steude U, Seelos K, Bötzel K: Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov Disord 2002, 17:138-144

Berg D, Niwar M, Maass S, Zimprich A, Möller JC, Wuellner U, Schmitz-Hübsch T, Klein C, Tan EK, Schöls L, Marsh L, Dawson TM, Janetzky B, Müller T, Woitalla D, Kostic V, Pramstaller PP, Oertel W, Bauer P, Krüger R, Gasser T, Riess O. Alpha-synuclein and Parkinson’s disease – implications from the screening of more than 1900 patients. Mov Disord 2005; 20(9):1191-1194

Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brüssel T, Schulte C, Maaß S, Nägele T, Wszolek ZK, Gasser T. Type and frequency of mutations in the LRRK2 gene in familiar and sporadic Parkinson’s disease. Brain 2005;128:3000-3011

Bergman H, Deuschl G. Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. Mov Disord 2002; 17 Suppl 3:28-40

Biskup S, Mueller J, Sharma M, Lichtner P, Zimprich A, Berg D, Wüllner U, Illig T, Meitinger T, Gasser T. Common variants of LRRK2 are not associated with sporadic Parkinson disease. Annals of Neurology 2005; 58:905-908

Bötzel K, Krack P: Deep Brain Stimulation for movement disorders. In: Brandt et al (Hrsg) Neurological Disorders Course and Treatment Academic Press 2003

Bötzel K, Krack P: Elektrische Hirnstimulation bei Bewegungsstörungen. In: Th. Brandt, J. Dichgans, H.C. Diener (Ed) Therapie und verlauf neurologischer Erkrankungen. Kohlhammer Stuttgart 2003

Bötzel K, Steude U. Indikationen der operativen Behandlung des Tremors. Deutsche medizinische Wochenschrift 1999, 124: 287-290

Bötzel K, Steude U: Tremorbehandlung bei Multipler Sklerose - Zitterpartie oder Zittertherapie. NeuroTransmitter 2003; 5:64-66

Brandstädter D, Lotze J, Spieker S, Ulm G, Oertel WH. Efficacy of Quetiapine in the treatment of dopamimetic psychosis in Parkinson`s disease. Mental dysfunction in movement disorders, 10.-13.October 2001, Montreal, Kanada. Mov Disord 2001; 16 Suppl 1: 32

Brandstädter D, Lotze J, Spieker S, Ulm G, Oertel WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2002; 58:160-1

Brandstädter D, Oertel WH. Psychosis and depression in Parkinson's disease. Free University Press Amsterdam 2002. Adv. Neurol 2003; 91: 371 - 381

Brandstädter D, Spieker S, Krieg C, Oertel WH Ulm G. The Parkinson Psychose Fragebogen- a new instrument for the early diagnosis of psychosis in Parkinson's disease. Deutscher Parkinson-Kongress, 7.-10. March 2001, Bochum

Buervenich S, Carmine A, Galter D, Shahabi HN, Johnels B, Holmberg B, Ahlberg J, Nissbrandt H, Eerola J, Hellström O,Tienari PJ, Matsuura T, Ashizawa T, Wüllner U, Klockgether T, Zimprich A, Gasser T, Hanson M, Singleton A, McMahon FJ, Anvret M, Sydow O, Olson L. A Rare Truncating Mutation in ADH1C (G78stop) Shows Significant Association with Parkinson's Disease in a Large International Sample. Arch Neurol (in press)

Buhmann C, Binkofski F, Klein C, Buchel C, van Eimeren T, Erdmann C, Hedrich K, Kasten M, Hagenah J, Deuschl G, Pramstaller PP, Siebner HR. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 2005; 128: 2281-2290

Buhmann C, Pramstaller PP, Binkofski F, Erdmann C, Hedrich K, Hagenah J, van Eimeren T, Buechel C, Deuschl G, Klein C, Siebner HR. Motor cortex reorganization in asymptomatic carriers of a single mutant PARKIN allele: a human model for presymptomatic parkinsonism. Brain 2005; 128:2281-2290

Ceballos-Baumann AO, Boecker H, Fogel W, Alesch F, Bartenstein P, Conrad B, Diederich N, von Falkenhayn I, Moringlane JR, Schwaiger M, Tronnier VM. Thalamic stimulation for essential tremor activates motor and deactivates vestibular cortex. Neurology 2001; 56(10):1347-54

Dauper J, Peschel T, Schrader C, Kohlmetz C, Joppich G, Nager W, Dengler R, Rollnik JD. Effects of subthalamic nucleus (STN) stimulation on motor cortex excitability. Neurology 2002; 59(5):700-6

Deep Brain Stimulation in Parkinson's Disease Study Group. Deep Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus Internus in Parkinson's Disease. N Engl J Med 2001; 345:356-363

Depboylu C, Matusch A, Tribl F, Zoriy M, Michel PP, Riederer P, Gerlach M, Becker S, Oertel WH, Höglinger GU. Glia Protects Neurons against Extracellular Human Neuromelanin. Neurodegenerative Dis 2007; 4: 218-226

Deuschl G. Elektrische Stimulation des Nucleus subthalamicus bei Morbus Parkinson: Indikation, Ergebnisse und Patientenmanagement. Akt Neurol 2000; 27 Suppl 1:1

Deuschl G. New treatment options for tremors. N Engl J Med 2000; 342:505-507

Deuschl G. Tiefenstimulation bei Bewegungsstörungen. Deutsches Ärzteblatt 2000; 97:2438 (Presentation of project 3 of the PCN)

Deuschl G, Bain P. Deep brain stimulation for trauma: Patient selection and evaluation. Mov Disord 2002; 17 Suppl 3:102-111

Deuschl G, Bergmann H. Pathophysiology of nonparkinsonian tremors. Mov Disord 2002; 17 Suppl 3:41-48

Deuschl G, Fogel W, Hahne M, Kupsch A, Muller D, Oechsner M, Sommer U, Ulm G, Vogt T, Volkmann J. Deep-brain stimulation for Parkinson's disease. J Neurol 2002; 249 Suppl 3:36-39

Deuschl G, Franke S. Tiefe Hirnstimulation bei fortgeschrittener Parkinson-Erkrankung. Nervenheilkunde 2007; 26: 251-255

Deuschl G, Krack P. Die Grenzen der medikamentösen Behandlung des M. Parkinson und des Tremors. Akt Neurol 2000; 27 Suppl 1:2-8

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloß M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel WH, Pinsker MO, Reichmann H, Reuß A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, for the German Parkinson Study Group, Neurostimulation Section. A Randomized Trial of Deep-Brain Stimulation for Parkinson’s Disease. N Engl J Med 2006; 355:896-908

Deuschl G, Volkmann J, Krack P. Deep brain stimulation for movement disorders Mov Disord 2002; 17 Suppl 3:1

Deuschl G, Wenzelburger R, Kopper F, Volkmann J. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards. J Neurol. 2003 Feb; 250 Suppl 1:I43-6

Diener HC (ed): Kompetenznetz Parkinson, Expertengruppe: Oertel WH, Deuschl G, Gasser T, Eggert K, Arnold G, Baas H, Przuntek H, Reichmann H, Riederer H, Spieker S, Trenkwalder C. Leitlinien Parkinson-Syndrome. Thieme-Verlag, 2. Auflage 2003

Diener HC, Weber R, et al. Klinische Studien im Bereich der Neurologie in Deutschland. Akt Neurol 2003; 30: 288-295

Dodel RC, Bornschein B, Oertel WH, Siebert U. Decision-Analytic Models for the Economic Evaluation of Treatment Options in Parkinson's Disease. Bartko (ed.) Parkinson's disease. 2003 (in press)

Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19: 1013-1038

Dodel RC, Berger K. Aspekte gesundheitsökonomischer Evaluationsforschung am Beispiel neurodegenerativer Erkrankungen. Neuroforum 2002; 1.02: 146-154

Dodel RC, Eggert K, Oertel WH. Economical Research on Parkinson's Disease: A Review of the Literature. Eur J Neurol 1999, 6 (suppl 2): 3-15

Dodel RC, Haacke C, Zamzow K, Pawelzik S, Spottke A, Rethfeldt M, Siebert U, Oertel WH, Schöffski O, Back T. Resource Utilization and costs of stroke unit care in Germany. Value of Health 2004

Dodel RC, Höffken U, Möller C, Oertel WH, Klockgether T, Siebert U. Dopamine Transporter Imaging and SPECT in the Diagnostic Work-up of Parkinson's Disease – A Decision-Analytical Approach. Mov Disord. 2003, Vol. 18, Suppl 7: 52-62

Dodel RC, Lohmüller F, Du Y, Eastwood B, Gocke P, Oertel WH, Gasser T. A polymorphism in the intronic region of the IL-1alpha gene and the risk for Parkinson's disease. Neurology 2001; 56:892-3

Dodel RC, Oertel WH. Lewy Körper Demenz. Akt Neurol. 2002; Sonderband: 499-502

Dodel RC, Oertel WH. Lewy-Körper Demenz. Frankfurter Parkinson-Symposium. Hoffmann LaRoche Grenzach-Whylen 2003; 91-118

Dodel R, Peter H, Spottke A, Noelker C, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G. Health-related quality of life in patients with narcolepsy. Sleep Med 2007

Dodel RC, Peter H, Spottke A, Walbert T, Mayer G. Evaluation of quality of life and healthcare utilization in Narcolepsy 2004

Dodel R, Peter H, Walbert T, Spottke A, Berger K, Siebert U, Fimmers R, Oertel WH, Kesper K, Becker HF, Mayer G. The Socioeconomic Impact of Narcolepsy. Sleep 2004

Dodel R, Rosenow F, Hamer HM. Die Kosten der Epilepsie in Deutschland. Gesundheitsökonimische Evaluaiton einer chronischen Krankheit. Pharm Unserer Zeit 2007; 36:298-205

Dodel R, Spottke A. Ökonomische Analyse des Parkinson-Syndroms. Nervenheilkunde 2007; 26: 256-259

Dodel RC, Spottke A, Koehne-Volland R, Smala A, Berger K, Oertel WH (2000) Social and economical costs of Parkinson's disease. Mov Dis 2000; 15 (suppl. 3): 3.

Dodel RC, Spottke A, Oertel WH. Lebensqualität und Kosten der Parkinson Krankheit. 12. Frankfurter Parkinson-Symposium 2000, Hoffmann LaRoche. Pharmakotherapie und funktionelle Neurochirurgie in der Behandlung der Parkinson-Krankheit, pp 201-226

Dodel RC, Spottke AE, Oertel WH. Cost-effectiveness of different therapies in patients with movement disorders. Reh Neural Repair 2002

Dodel RC, Spottke EA, Oertel WH. Lebensqualität und Kosten neurochirurgischer Verfahren in der Behandlung der Parkinson-Erkrankung. Akt Neurol 2000; 27 S1: S61-S69

Dodel RC, Volkmann J, Spottke AE, Smala A, Berger K, Krack P, Oertel WH. Cost-effectivness of deep brain stimulation in patients with Parkinson's disease. Value in Health 2001; 4: 518-519

Dodel R, Walbert T, Siebert U. Entscheidungsanalysen in der Medizinischen Ökonomie Ökonomie - am Beispiel der Parkinson-Krankheit. Akt Neurol 2003; 30, Suppl. 2:1-11

Eggert K. Morbus Parkinson – früh erkennen, sicher behandeln (Leitlinien , CME). Heilberufe 2005; 9:28-33

Eggert K. Morbus Parkinson – früh erkennen, sicher behandeln. Der Kassenarzt 2006; 4: 28-32

Eggert K, Antony G, Franke S, Oertel WH. Protected data collection for the Gene Bank Parkinson’s Disease Germany (GEPARD) of the Competence Network on Parkinson’s Disease (CNP). it 2007

Eggert K, Baas H, Deuschl G, Dodel R, Franke S, Gasser T, Klockgether T, Reichmann H, Trenkwalder C, Wüllner U, Oertel WH. Das Kompetenznetz Parkinson. Nervenheilkunde 2007; 26: 239-240

Eggert K, Baas H, Deuschl G, Dodel R, Gasser T, Klockgether T, Reichmann H, Trenkwalder C, Wüllner U, Oertel WH. Das Kompetenznetz Parkinson. Medizinische Welt 2005; 3:69-72

Eggert K, Baas H, Deuschl G, Dodel R, Gasser T, Klockgether T, Reichmann H, Trenkwalder C, Wüllner U, Oertel WH. Das Kompetenznetz Parkinson. Nervenheilkunde 2005; 24:4-8

Eggert K, Dodel R, Franke S, Oertel WH. Leitlinien für Diagnose und Therapie der Parkinson-Syndrome. Nervenheilkunde 2007; 26: 269-276

Eggert KM, Franke S. Wenn die Bewegung erstarrt. Kompetenz in Sachen Parkinson: Netzwerk-Zentrale in der Marburger Neurologie. Marburger UniJournal 2003; 17:19-21

Eggert K, Franke S. Diagnose des idiopathischen Parkinson-Syndroms. Frühe Diagnose entscheidend für die Prognose der Krankheit. Neuropsychiatrische Zeitung Juni 2005, 9

Eggert K, Franke S. Frühtherapie des idiopathischen Parkinson-Syndroms. Das Alter entscheidet mit welches Medikament verabreicht werden soll. Neuropsychiatrische Zeitung Juni 2005, 10

Eggert K, Oertel WH. State of the Art – Parkinson-Krankheit. PharmaFokus ZNS 2006; 3:9-11

Eggert K, A, Oertel WH. Neurotrophe Faktoren. 12. Frankfurter Parkinson-Symposium 2000, Hoffmann LaRoche. Pharmakotherapie und funktionelle Neurochirurgie in der Behandlung der Parkinson-Krankheit, pp 279-285

Eggert K, Oertel WH, Stiasny-Kolster K, Trenkwalder C. Entscheidungshilfe für den ambulanten und stationären Bereich: So bekommen Sie Parkinson und Restless Legs in den Griff. Neurology & Psychiatrie 2005; 7:34-40

Eggert K, Spieker S, Odin P, Oertel WH . Kompetenznetz Parkinson-Syndrom: Die ersten 2 1/2 Jahre, was dann? 13. Frankfurter Parkinson-Symposium 2002, Hoffmann LaRoche. Neuropathologie der Parkinson-Syndroms. Neue Entwicklungen in der Therapie, pp 191-198

Eggert K, Wick R, Oertel WH. Netzwerke Parkinson Syndrom Deutschland und Europa. 14. Frankfurter Parkinson-Symposium 2004, Editiones Roche, Roche Interaktiv; 94-104

Eggert KM, Wüllner U, Antony G, Gasser T, Janetzky B, Klein C, Schöls L, Oertel WH. Data Protection in Biomaterial Banks for Parkinson’s Disease Research: The Model of GEPARD (Gene Bank Parkinson’s Disease Germany). Mov Disord 2007; 22: 611-618

Ehret R, Reuther P, Morbus Parkinson – Patienten werden immer jünger. Neurotransmitter 2001, Sonderheft 1:47-49

Eichhorn T, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16:1176-7

Engelmann, Dodel B, Möller JC, Dodel R, Oertel WH. Dopaminerge Medikamente und Schlafattacken bei Patienten mit Parkinson-Krankheit: Rechtliche Aspekte. 13. Frankfurter Parkinson-Symposium 2002, Hoffmann LaRoche. Neuropathologie der Parkinson-Syndroms. Neue Entwicklungen in der Therapie, pp 175-180

Epifanov Y, Dodel R, Haacke C, Schaeg M, Schoffski O, Hennerici M, Back T. Costs of acute stroke care on regular neurological wards: A comparison with stroke unit setting. Health Policy 2006 Aug 21 [Epub ahead of print]

Fogel W, Krause M, Tronnier M. Ergebnisse der STN-Stimulation im Vergleich mit anderen stereotaktischen Verfahren. Akt Neurol 2000; 27 Suppl 1:9-15

Fölsch U, Oertel WH, Rauch C, Hirsch M, Jaeger T. Kompetenznetze in der Medizin: Eine Standortbestimmung. Deutsches Ärzteblatt 2002, 99, 7:A-413

Funk Th, Vesper J, Sarem-Aslani A. Vorstellung eines 2- Elektrodenimpulsgenerators für die chronische Tiefenhirnstimulation. Akt Neurol 2000; 27 Suppl 1:48-52

Fuß G, Spiegel J, Magnus-T, Moringlane JR, Becker G, Dillmann U: Case Report: Improvement of apraxia of lid opening by STN-Stimulation in a 70-year old patient with parkinson´s disease. Minimally Invasive Neurosurgery 2004 (in press)

Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, Del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; on behalf of the EMSA-SG. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005; 112:1677-1686

Georgi JC, Stippich C, Tronnier VM, Heiland S. Active deep brain stimulation during MRI: A feasibility study. Magn Reson Med. 2004 Feb;51(2):380-8

Gossrau G, Fuessel M, Kempe A, Herting B, Koch R, Reichmann H, Lampe JB. HLA and clinical course of Parkinson’s disease.

Gossrau G, Herting B, Möckel S, Kempe A, Koch R, Reichmann H, Lampe JB. Analysis of the Prion Protein gene codon 129 in Idiopathic Parkinson’s Disease. J Neural Transm 2006;113:331-337

Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006; 37:193-198

Haag A, Dodel R, Oertel WH. M. Parkinson. Einführung in das Krankheitsbild. Marburger Verlag 2003

Hahne M, Jost W, Fischer E, Ziegler V, Schlesinger S, Griewing. Stellenwert des non-ergolinen Dopaminrezeptoragonisten Ropinirol bei fortgeschrittener Parkinson-Krankheit im höheren Lebensalter und motorischen Komplikationen. Akt Neurol 2005; 32:22

Hahne M, Jost W, Kraus P, Fischer E, Griewing. Therapie des Parkinsontremors mit dem non-ergolinen Dopaminagonisten Ropinirol. Akt Neurol 2005; 32:222

Halbig TD, Gruber D, Kopp UA, Schneider GH, Trottenberg T, Kupsch A. Pallidal stimulation in dystonia: effects on cognition, mood, and quality of life. J Neurol Neurosurg Psychiatry 2005; 76:1713-1716

Hamel W, Fietzek U, Morsnowski A, Schrader B, Herzog J, Weinert D, Pfister G, Müller D, Volkmann J, Deuschl G, Mehdorn HM. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts. J Neurol Neurosurg Psychiatry 2003; 74 (8): 1036-46

Hamel W, Schrader B, Weinert D, Herzog J, Muller D, Deuschl G, Volkmann J, Mehdorn HM. Technical complication in deep brain stimulation. Zentralbl Neurochir 2002; 63(3):124-7

Hamel W, Schrader B, Weinert D, Herzog J, Volkmann J, Deuschl G, Muller D, Mehdorn HM. MRI- and skull x-ray-based approaches to evaluate the position of deep brain stimulation electrode contacts - a technical note. Zentralbl Neurochir 2002; 63(2):65-9

Hamer H, Spottke A, Aletsee A, Knake S, Reis J, Strzelcyk A, Oertel W, Rosenow F, Dodel R. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006

Haslinger B, Boecker H, Buchel C, Vesper J, Tronnier VM, Pfister R, Alesch F, Moringlane JR, Krauss JK, Conrad B, Schwaiger M, Ceballos-Baumann AO. Differential modulation of subcortical target and cortex during deep brain stimulation. Neuroimage 2003; 18(2):517-2

Healy DG, Abou-Sleiman P, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Pellecchia MT, Cardozo A, Quinn N, Goldstein DB, Wood N. Homozygosity for a functional polymorphism regulating dopamine beta hydroxylase plasma activity protects against Parkinson's disease. Ann Neurol 2004, March, Vol. 55 (3): 443-446

Healy DG, Abou-Sleiman PA, Quinn N, Ahmadi KR, Ozawa T, Kamm C, Wüllner U, Oertel WH, Bürk K, Dupont E, Pellecchia MT, Tolosa E, Gasser T, Holton JL, Revesz T, Goldstein DB, Lees AJ, Wood NW and the European MSA Study Group. The UCHL-1 Gene in Multiple System Atrophy: A Haplotype Tagging Approach. Mov Disord 2005; 20:1338-1374

Heberlein I, Maniak S, Schmidt S, Vieregge P. Clinical epidemiology of familial parkinsonism: Cognitive impairment in patients with idiopathic Parkinson´s disease (PD) and their first-degree relatives. 3. Deutscher Parkinson-Kongress, Dresden, 5. - 8.3.03

Hedrich K, Pramstaller PP, Stübke K, Hiller A, Kabakci K, Purmann S, Kasten M, Scaglione C, chwinger E, Volkmann J, Kostic V, Vieregge P, Martinelli P, Abbruzzese G, Klein C, Zühlke C. Premutations in the FMR1 Gene as a Modifying Factor in Parkin-Associated Parkinson’s Disease? Movement Disord 2005; 20:1060-1062

Heinermann A, Baum E, Höglinger G, Oertel WH. Frühdiagnose und Erkennung des Morbus Parkinson im Rahmen des MedNet Parkinson Projektes (Teilprojekt 4). Zeitung für Allgemeinmedizin. 2000; 75:7

Heinermann A, Baum E, Höglinger G, Rissling I, Ries V, Donner-Banzhoff N, Oertel WH. Evaluation von Screeninginstrumenten in der Allgemeinarztpraxis zur Früherkennung des Morbes Parkinson. Zeitung für Allgemeinmedizin. 2001; 77: 22

Herzog J, Deuschl G, Volkmann J. Die tiefe Hirnstimulation in der Therapie des idiopathischen Parkinsonsyndroms. Nervenheilkunde 2003; 22: 498-503

Herzog J, Reiff J, Krack P, Witt K, Schrader B, Müller D, Deuschl G. Manic epsiode with psychotic symptoms induced by subthalamic deep brain stimulation in a patient with Parkinson's disease. Mov Disord 2003, Nov, 18 (11): 1382-1384

Herzog J, Volkmann J, Krack P, Kopper F, Pötter M, Lorenz D, Steinbach M, Klebe S, Hamel W, Schrader B, Weinert D, Mehdorn HM, Deuschl G. Two year follow up of subthalamic deep brain stimulation in Parkinson´s disease. Mov Disord 2003, Vol 18 (11): 1332-1337

Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Herzog H, Volkmann J, Deuschl G, Fink GR. Subthalamic deep brain stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain 2006; 129: 3366-3375

Hesselmann V, Sorger B, Girnus R, Lasek K, Maarouf M, Wedekind C, Bunke J, Schulte O, Krug B, Lackner K, Sturm V. Intraoperative functional MRI as a new approach to monitor deep brain stimulation in Parkinson's disease. Eur Radiol. 2003 Sep 26 [Epub ahead of print]

Hilker R, Herholz K, Schuster A, Voges J, Ghaemi M, Sturm V, Wienhard K, Heiss WD. The antiparkinsonian effects of deep brain stimulation in the subthalamic nucleus are not mediated by an increase of tonic striatal dopamine receptor stimulation: evidence from serial [11C]raclopride-PET in parkinsonian humans. Neuroimage 2002; 16: 63

Hilker R, Kracht L, Weinert M, Ghaemi M, Herholz K, Sturm V, Heiss WD. Modulation of developmental stuttering severity by bilateral high-frequency stimulation of the subthalamic nucleus: evidence of basal ganglia contribution to abnormal speech performance. J Neural Transm 2001; 108 (2): XIV

Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A, Herholz K, Wienhard K, Sturm V, Heiss WD. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 2003; 18(1):41-8

Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, Sturm V, Heiss WD. Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET. J Neural Transm 2002; 109(10):1257-64

Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, Lehrke R, Koulousakis A, Herholz K, Sturm V, Heiss WD. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 2004, 24 (1): 7-16

Hilker R, Voges J, Weisenbach S, Kalbe E, Ghaemi M, Koulousakis A, Sturm V, Heiss WD. High frequency stimulation of the subthalamic nucleus affects metabolic activity in limbic, associative and cerebellar circuits in patients with advanced Parkinson's disease. Akt Neurol 2003; 30 (Suppl 1): 236

Höglinger GU, Baum E, Ries V, Rissling I, Brandstädter D, Lorenz D, Strate P, Ulm G, Krieg JC, Deuschl G, Oertel WH. Evaluation of a screening procedure for de novo parkinsonism at the level of general practitioners. J Neural Transm 2001; 108: XXVII

Höglinger GU, Breunig JJ, Depboylu C, Rouaux C, Michel PP, Alvarez-Fischer D, Boutillier AL, DeGregori J, Oertel WH, Rakic P, Hirsch E, Hunot S. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. Proc Natl Acad Sci USA 2007; 27: 3585-3590

Höglinger GU, Féger J, Prigent A, Michel P, Parain K, Champy P, Ruberg M, Oertel WH, Hirsch EC. Chronic systemic complex I inhibition induces a hyopkinetic multisystem degeneration in rats. J Neurochem 2003; 84(3): 491-502

Hoeglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005; 95:930-939

Höglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, Spieker S, Deuschl G, Baum E, Oertel WH. Enhancing Recognition of Early Parkinsonism in the Community. Mov Disord 2004 (in press)

Hoeglinger G, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nature Neuroscience 2005; 7:726-735

Hofer A, Berg D, Asmus F, Niwarr M, Ransmayr G, Riemenschneider M, Bonelli SB, Steffelbauer M, Ceballos-Baumann A, Haussermann P, Behnke S, Krüger R, Prestel J, Sharma M, Zimprich A, Riess O, Gasser T. The role of ά-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies. J Neural Transm 2005; 112:1249-54

Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmoller J. L -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750-1755

Kettenmann H, Gibson M, Hrsg. Addendum zu Neuroforum. Schneider A, Spieker S, Oertel WH. Morbus Parkinson. Kosmos Gehirn, Berlin 2001, ISBN 0947-0875

Klein C, Djarmati A, Hedrich K, Schäfer N, Scaglione C, Marchese R, Kock N, Schüle B, Hiller A, Lohnau T, Winkler S, Wiegers K, Hering R, Bauer P, Riess O, Abbruzzese G, Martinelli P, Pramstaller P. PINK 1, Parkin, and DJ-1 mutatins in Italian patients with early-onset parkinsonism. Eur J Hum Genet 2005; 13:1086-1093

Klein C, Ozelius LJ. Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol 2002; 15(4):491-7

Klinikum Aktuell, Zeitung des Klinikums der Philipps-Universität Marburg 2003; 25-28

Koch W, Münzing W, Geworski L, Sonnenschein W, Höffken H, Czech N, Tatsch K. Zentrumübergreifende Messungen an einem Basalganglien-Phantom zur Vereinheitlichung der SPECT Diagnostik des dopaminergen Systems. Abstract: in 'Nuklearmedizin als Paradigma molekularer Bildgebung', Hrsg.: Brink I. et al. Blackwell, Berlin, 2002; S. 20

Körner Y, Meindorfner C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger HP. Predictors of Sudden Onset of Sleep in Parkinson's disease. Mov Disord 2004

Körner Y, Roth C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger H-P. Zusammenhang zwischen selbstberichteter Tagesmüdigkeit und selbstberichteter Schlafstörungen vor und nach einer Erkrankung an M. Parkinson – Fragebogendaten von 6620 Parkinson-Patienten. Somnologie 2003; 7: 79-88

Koerner Y, Roth C, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP (2003). Sudden Onset of Sleep (SOS) in Parkinson's disease. American Professional Sleep Societies (APSS) 17th Annual Meeting, Chicago. 03. - 08.06.2003. Sleep 2003 (Suppl.); 26: A 333

Krack P, Müller D, Benabid AL, Deuschl G, Pollak P. Tiefe Hirnstimulation bei M. Parkinson, Tremor und Dystonie: Patientenselektion. Akt Neurol 2000; 27 Suppl 1:16-22

Krack P, Müller D, Mehdorn HM, Deuschl G. Chirurgische Behandlung von Bewegungsstörungen. Akt Neurol 2000; 27 Suppl1:197-211

Krack P, Poepping M, Weinert D, Schrader B, Deuschl G. Thalamic, pallidal or subthalamic surgery for Parkinson's disease. J Neurol 2000; 247:122-134

Krause M, Fogel W, Heck A, Hacke W, Bonsanto M, Trenkwalder C, Tronnier V. Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry 2001; 70(4):464-70

Kuhn AA, Brandt SA, Kupsch A, Trottenberg T, Brocke J, Irlbacher K, Schneider GH, Meyer BU. Comparison of motor effects following subcortical electrical stimulation through electrodes in the globus pallidus internus and cortical transcranial magnetic stimulation. Exp Brain Res. 2003 Nov 22

Kuhn AA, Meyer BU, Trottenberg T, Brandt SA, Schneider GH, Kupsch A. Modulation of motor cortex excitability by pallidal stimulation in patients with severe dystonia. Neurology 2003; 60(5):768-74

Kuhn AA, Trottenberg T, Kupsch A, Meyer BU. Pseudobilateral hand motor responses evoked by transcranial magnetic stimulation in patients with deep brain stimulation. Clin Neurophysiol. 2002; 113:341-5

Kuhn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider GH, Yarrow K, Brown P. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain 2004; DOI: 10.1093/brain/awh106

Kupsch A, Benecke R, Muller J, Trottenberg T, Schneider GH, Poewe W, Eisner W, Wolters A, Muller JU, Deuschl G, Pinsker MO, Skogseid IM, Roeste GK, Vollmer-Haase J, Brentrup A, Krause M, Tronnier V, Schnitzler A, Voges J, Nikkhah G, Vesper J, Naumann M, Volkmann J; Deep-Brain Stimulation for Dystonia Study Group. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355: 1978-1990

Kupsch A, Earl C. Neurosurgical interventions in the treatment of idiopathic Parkinson disease: neurostimulation and neural implantation. J Mol Med 1999; 77:178-84

Kupsch A, Klaffke S, Kuhn AA, Meissner W, Arnold G, Schneider GH, Maier-Hauff K, Trottenberg T. The effects of frequency in pallidal deep brain stimulation for primary dystonia. J Neurol 2003; 250(10):1201-5

Kupsch A, Kuehn A, Klaffke S, Meissner W, Harnack D, Winter C, Haelbig TD, Kivi A, Arnold G, Einhaupl KM, Schneider GH, Trottenberg T. Deep brain stimulation in dystonia. J Neurol. 2003 Feb; 250 Suppl 1:I47-52

Kupsch A, Trottenberg T, Meissner W, Funk T. Neurostimulation of the ventral intermediate thalamic nucleus alleviates hereditary essential myoclonus. J Neurol Neurosurg Psychiatry 1999; 67:415-6

Lange KW, Tucha O, Alders L, Preier M, Csoti I, Merz B, Mark G, Herting B, Fornadi F, Reichmann H, Vieregge P, Reiners K, Becker G, Naumann M. Differentiation of parkinsonian syndromes according in differences in executive functions. J Neural Transm (2003) 110: 983-995

Lindgren P, von Campenhausen S, Spottke E, Siebert U, Dodel R. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; Suppl 1:68-73

Linnebank M, Kölsch H, Linnebank A, Wienker TF, Suormala T, Fowler B, Jeub M, Koch HG, Klockgether T, Heun R, Wüllner U. Genetics of homocysteine metabolism in Parkinson's disease. European Journal of Human Genetics 2004

Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A. How much phenotypic variation can be attributed to parkin genotype, Ann Neurol 2003; 54: 176-185

Lu L, Neff F, Dun Z, Hemmer B, Oertel WH, Schlegel J, Hartmann A. Gene expression profiles derived from single cells in human postmortem brain. Brain Res Protoc. 2004 Apr; 13(1):18-25.

Lubik S, Fogel W, Tronnier V, Krause M, Konig J, Jost WH. Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation. J Neural Transm 2006; 113:163-173

Macht M, Kaussner Y, Möller JC, Stiasny-Kolster K, Eggert KM, Krüger HP, Ellgring H. Predictors of freezing in Parkinson’s disease: A survey of 6,620 patients. Mov Disord. 2007; 15: 953-956

Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Krüger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JPA, Andrade M, Rocca WA, and the UCHL1Global Genetics Consortium. UCHL1 is a Parkinson's Disease Susceptibility Gene. Ann Neurol 2004 Apr;55(4):512-21. (in press)

Mayer G, Stiasny-Kolster K, Dörr Y, Möller JC, Oertel WH. Olfactory dysfunction in patients with REM sleep behaviour disorder. American Professional Sleep Societies (APSS) 17th Annual Meeting, Chicago. 03. - 08.06.03. Sleep 2003 (Suppl.); 26: A 277

Mehdorn HM, Pinsker MO, Volkmann J, Hamel W, Schrader B, Stiller U, Herzog J, Deuschl G. Deep brain stimulation for idiopathic or secondary movement disorders. Acta Neurochir 2005; 93: 105-111

Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 2005; 20:832-842

Meissner W, Harnack D, Hoessle N, Bezard E, Winter C, Morgenstern R, Kupsch A. High frequency stimulation of the entopeduncular nuclues has no effect on striatal dopaminergic transmission. Neurochem Int. 2004 Mar; 44(4): 281-286

Meissner W, Harnack D, Paul G, Reum T, Sohr R, Morgenstern R, Kupsch A. Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. Neurosci Lett 2002; 328(2):105-8

Meissner W, Harnack D, Reese R, Paul G, Winter C, Morgenstern R, Kupsch A. High frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J Neurochem 2003; 85(3):601-9

Meissner W, Paul G, Reum T, Reese R, Sohr R, Morgenstern R, Kupsch A. The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat. Neurosci Lett 2000; 296:149-152

Meissner W, Reum T, Paul G, Harnack D, Sohr R, Morgenstern R, Kupsch A. Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett 2001; 303:165-168

Meissner W, Trottenberg T, Klaffke S, Paul G, Kuhn AA, Arnold G, Einhaeupl KM, Kupsch A.

Merschdorf U, Berg D, Csoti I, Fornadi F, Merz B, Naumann M, Becker G, Supprian T. Psychopathological Symptoms of Depression in Parkinson's Disease Compared to Major Depression. Psychopathology 2003; 36: 221-225

Metz A, Baum E, Rissling I, Höglinger G, Ries V, Heinermann A, Oertel WH: Langzeitergebnisse eines Screenings auf M. Parkinson in Allgemeinarztpraxen. Zeitung für Allgemeinmedizin. 2003; 79:16

Möller JC, Depboylu C, Kölsch H, Lohmüller F, Bandmann O, Gocke P, Du Y,Paus M, Wüllner U. Gasser T, Oertel WH, Klockgether T, Dodel RC. Lack of association between the IL-1a (-889) polymorphism and early-onset Parkinson's disease. Neurosci Lett 2004 Apr 15; 359(3):195-197

Moeller JC, Koerner Y, Dodel RC, Meindorfner C, Stiasny-Kolster K, Spottke A, Krüger HP, Oertel WH. Pharmacotherapy of Parkinson’s disease in Germany. J Neurol 2005; 252:926-935

Moeller JC, Koerner Y, Cassel W, Meindorfner C, Krüger HP, Oertel WH, Stiasny-Kolster. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Medicine (in press)

Möller JC, Leinweber B, Rissling I, Oertel WH, Bandmann O, Schmidt HHJ. The prevalence of the H1069Q mutation in ATP7B in discordant pairs with early-onset Parkinson’s disease. Mov Disord (in press)

Moeller JC, Rethfeldt M, Koerner Y, Stiasny-Kolster K, Cassel W, Meindorfner CD, Rissling I, Krüger HP, Oertel WH. Daytime sleep latency in medication-matched PD patients with and without sudden onset of sleep. Mov Disord 2005; 20:1620-1622

Möller JC, Stiasny K, Cassel W, Peter JH, Kruger HP, Oertel WH. Sleep attacks in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists. Nervenarzt 2000; 71:670-6

Moringlane JR, Putzer M, Barry WJ. Bilateral high-frequency electrical impulses to the thalamus reduce voice tremor: acoustic and electroglottographic analysis. A case report. Eur Arch Otorhinolaryngol. 2003 Oct 24 [Epub ahead of print]

Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, Wuellner U, Meitinger T, Gasser T. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 2005; 57(4):535-541

Muller T, Dodel R, Fritze J. Cost and quality aspects in the treatment of Parkinson's disease. Z Arztl Fortbild Qualitatssich 2006;100(4):291-295

Oertel WH. The Competence Network Parkinson in Germany. Moving Along 2003; Vol. 5, Issue 2, Spring 2003

Oertel WH. Hoffnung der Neurologen. Künftig nicht Symptome, sondern Ursachen behandeln. Med Review 2005; 11:2-4

Oertel WH. Parkinsonforschung 2005. Arzt & Wissenschaft Edition Med 2005; 8

Oertel WH. Rivastigmin zur Behandlung der Parkinson-Demenz zugelassen. Nervenheilkunde 2006; 25:596-597

Oertel WH, Dorloechter M. Changing Scene of National and EU Funding in Europe. Moving Along 2006; 8:4

Oertel WH, Eggert K. Was gibt es Neues in der Parkinson-Therapieentwicklung. 13. Frankfurter Parkinson-Symposium 2002, Hoffmann LaRoche. Neuropathologie der Parkinson-Syndroms und neue Entwicklungen in der Therapie, pp 231-234

Oertel WH, Eggert KM. Das Kompetenznetz Parkinson. dPV-Nachrichten 2004, 91:12

Oertel WH, Eggert K, Antony G, Franke S, Deuschl G, Gasser T, Hirsch M. Kompetenznetz Parkinson - Verbesserung der Gesundheitsversorgung. Deutsches Ärzteblatt, 19. Jahrgang, Praxis-Computer, September 2003, Ausgabe 3/03

Oertel WH, Fahn S: Parkinsonism. In: Brandt T, Diener HC, Caplan LR, Kennard C, Dichgans J (eds), Neurological disorders: course and treatment. 2003, 2nd edition, Chapter 74. Academic Press, San Diego, California, pp. 1021-1079

Oertel WH, Gerstner A, Höffken H, Dodel RC, Eggert KM , Möller JC. Role of Dopamine Transporter SPECT for the Practitioner and the General Neurologist. Mov Disord 2003; Vol. 18, Suppl. 7: 9-15

Oertel WH, Höglinger GU, Caraceni T, Girottie F, Eichhorn T, Spottke A, Krieg JC, Poewe W. Depression in Parkinson's disease: An update. In Calne D, Calne SM (eds.), Parkinson's disease. Chapter 39. Lippincott-Williams-Wilkins 2001, Philadelphia. Adv Neurology 86, 373-383

Oertel WH, Möller JC: Rare degenerative syndromes associated with Parkinsonism. In: Watts RL, Koller WC (eds), Chapter 24, Movement disorders - Neurologic Principles and Practice. 2nd Edition 2004. McGraw-Hill Inc.

Oertel WH, Schulz G: Parkinson Syndrome. In: Th. Brandt, J. Dichgans, H.C. Diener (Ed) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer-Verlag Stuttgart 2003; 4. Auflage, Kapitel H 2, pp 847-880

Oertel WH, Wächter T, Quinn NP, Ulm G, Brandstädter D. Reduced genital sensitivity as an anamnestic feature in female patients with multiple system atrophy. Mov Disord 2003; 18: 430-432

Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW, European MSA study group. The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry 2006; 77:464-467

Pakszys W (ed): Oertel WH, Deuschl G, Gasser T, Eggert K, Arnold G, Baas H, Przuntek H, Reichmann H, Riederer H, Spieker S, Trenkwalder C. Guidelines for parkinsonian syndromes in Germany 2003. Textbook Progress in PD diagnosis, monitoring and treatment (in press)

Paul G, Reum T, Meissner W, Marburger A, Sohr R, Morgenstern R, Kupsch A. High frequency stimulation of the subthalamic nucleus. Neuroreport 2000; 11:441-444

Paus S, Seeger G, Brecht HM, Köster J, El-Faddagh M, Nöthen M, Klockgether T, Wüllner U. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in PD. Mov Disord 2004 (in press)

Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicenter study. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):713-20

Putzer M, Barry WJ, Moringlane JR, Fuss G, Spiegel J, Dillmann U, Sittinger H. Effect of deep brain stimulation on glottal phonation in patients with Parkinson's disease and multiple sclerosis; Folia Phoniatr Logop. 2003; 55(5):220-32

Redaktion. Kompetenznetz Parkinson macht große Fortschritte, Geriatrie Journal 2002, 1-2:9

Redaktion. Verbindung von Forschung und Praxis, Kompetenznetz Parkinsn, Neuro-Psychiatrische Nachrichten 2001: 3, 5

Reng CM, Debold P, Adelhard K, Pommerening K. Vernetzte medizinische Forschung - Akzeptiertes Datenschutzkonzept. Deutsches Ärzteblatt 2003, Jg. 100, Heft 33. Abstracts der 47. Jahrestagung der GMDS vom 08. - 12.09.2002 in Berlin und der 10. Jahrestagung der DAE vom 09. - 11.09.2002 in Berlin. Nr. 382, Nr. 804, Nr. 805

Reuter P, Spieker S, Ehret R, Gerstner A, Kämpfer M, Simonow A, Oertel WH, Vermeij D. Disease-Management-Programm Parkinson: Startschuss für eine bessere Versorgungsqualität. Neurotransmitter 2003, 11, 28-29

Reuther M, Spottke EA, Dodel RC, Smala A, Berger K, Athen O, Köhne-Volland R, Brandstätter D, Oertel WH. Assessment of the quality of life in Parkinson's disease. J Neural Transm 2001; 108: 26

Reuther M, Spottke A, Klotsche J, Riedel O, Peter H, Berger K, Athen O, Köhne-Volland R, Dodel R. Assessing Health-Related Quality of Life in Patients with Parkinson’s Disease in a prospective longitudinal study. Parkinsonism Relat D 2007; 13:108-114

Rissling I, Koerner Y, Geller F, Stiasny-Kolster K, Oertel WH, Moeller JC. Preprohypocretin polymorphismus in Parkinson’s disease reporting “sleep attacks”. Sleep 2006; 1:108-111

Schenk T, Baur B, Steude U, Botzel K. Effects of deep brain stimulation on prehensile movements in PD patients are less pronounced when external timing cues are provided. Neuropsychologia. 2003;41(7):783-94

Schipper HI, Gross A, Franke S, Roales-Welsch S. Pflege von Patienten mit Parkinson-Syndromen. Leben mit dem Zittern. Heilberufe 2005; 9:12-15

Schmaljohann J, Gundisch D, Minnerop M, Bucerius J, Joe A, Reinhardt M, Guhlke S, Biersack HJ, Wüllner U. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson’s disease. Nuclear Medicine and Biology 2006; 3:305-309

Schmidt K, Oertel WH. Parkinson: Zittern ohne Ende. Gehirn & Geist 2005 Sep.

Schmidt S, Heberlein I, Maniak S, Vieregge P: Telefon-Screening zur Erfassung kognitiver Beeinträchtigungen in der Allgemeinbevölkerung – Eine Validierungsstudie. Dt. Ges. f. Neurologie, Aachen, Sept. 2001. Akt. Neurologie 2001; 28:S171

Schmidt S, Heberlein I, Maniak S, Vieregge P: Telephone screening for the epidemiological study of cognitive impairment in patients with Parkinson´s disease and other neurological conditions. Symposium Mental and Behavioral Dysfunction in Movement Disorders, Toronto, Oct. 2001. Movement Disorders, Vol. 16, Suppl. 1, 2001

Schmitt I, Khazneh H, Healy DG, Wood NW, Koelsch H, Klockgether T, Wüllner U. A significant association of the truncating mutation in ADH1C (G78stop) with multiple system atrophy depends on ethnic background. Mov Disord (in press)

Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 2003; 60(3):296-302

Schrader B, Hamel W, Weinert D, Mehdorn HM. Documentation of electrode localization. Mov Disord 2002; 17 Suppl 3:167-174

Schrag A, Dodel RC, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 2007; 15;22: 938-45

Schroeder U, Kuehler A, Haslinger B, Erhard P, Fogel W, Tronnier VM, Lange KW, Boecker H, Ceballos-Baumann AO. Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study. Brain 2002; 125(Pt 9):1995-2004

Schroeder U, Kuehler A, Lange KW, Haslinger B, Tronnier VM, Krause M, Pfister R, Boecker H, Ceballos-Baumann AO. Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Ann Neurol. 2003 Oct;54(4):445-50

Schubert T, Volkmann J, Muller U, Sturm V, Voges J, Freund HJ, Von Cramon DY. Effects of pallidal deep brain stimulation and levodopa treatment on reaction-time performance in Parkinson's disease. Exp Brain Res 2002; 144(1):8-16

Schulte C, Lichtner P, Walter U, Wüllner U, Zimprich A, Illig T, Berg D, Gasser T. Frequency of LRRK2 mutations in sporadic Parkinson’s disease patients. Neuroscience letters 2007

Schulte J, Wehrmann R, Wellbrock R. Das Datenschutzkonzept des Kompetenznetz Parkinson. DuD Datenschutz und Datensicherheit 26 (2002)

Schulte T, Brecht S, Herdegen T, Illert M, Mehdorn HM, Hamel W. Induction of immediate early gene expression by high-frequency stimulation of the subthalamic nucleus in rats. Neuroscience 2006; 138:1377-1385

Schulz JB, Benecke R, Dodel R, Eggert K, Fogel W, Gerlach M, Reichmann H, Riederer P, Schwartz A, Winkler J. Strukturierte Diagnostik bei Parkinson-Syndromen. Akt Neurol 2005; 32:97-101

Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G, Juenemann KP, Braun P. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol, 2004 Jan. 55 (1): 118-120 (in press)

Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic Assessment of Decision Models in Parkinson's Disease. Value of Health. 2004 (in press)

Silberstein P, Kuhn AA, Kupsch A, Trottenberg T, Insola A, Di Lazzaro, Mazzone M, Oiliviero A,. Aziz T, Brown P, 2003. Local field potentials changes in the globus pallidus of patients with dystonia and Parkinson´s disease. Brain 2004 (in press)

Silberstein P, Kuhn AA, Kupsch A, Trottenberg T, Krauss JK, Wohrle JC, Mazzone P, Insola A, Di Lazzaro V, Oliviero A, Aziz T, Brown P. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 2003; 126: 2597-608

Smala A, Athen O, Spottke A, Reuther M, R. Köhne-Volland, Oertel WH, Berger K, Dodel RC. Cost-effectiveness of cabergoline in the treatment of Parkinson's disease. Mov Disord 2004 (in press)

Smala AM, Spottke EA, Machat O, Siebert U, Meyer D, Köhne-Volland R, Reuther M, DuChane J, Oertel WH, Berger KB, Dodel RC: Cabergoline versus levodopa monotherapy: A decision analysis. Mov Disord 2003, Vol. 18, Nr. 8, pp 898 - 905

Spiegel J, Fuß G, Backens G, Reith W, Magnus T, Becker G, Moringlane JR, Dillmann U. Transient dystonia in a parkinsonian patient with deep brain stimulation electrodes after cranial magnetic resonance imaging. J Neurosurg 2003; 99:772-774

Spieker S, Ehret R, Gerstner A, Kämpfer M, Simonow A, Oertel W, Vermeij D, Reuther P. Ein Disease-management Programm (DMP-Parkinson) für die Langzeitbehandlung von Patienten mit Parkinson'scher Erkrankung (PD). Neurotransmitter 2002

Spottke AE, Dodel RC, Reuther M, Smala A, Berger K, Athen O, Koehne-Volland, Oertel WH. Costs of Parkinson's disease a comparison 1995 and 2000. J Neural Transm 2001; 108: 26

Spottke EA, Reuther M, Athen O et al. Healthcare utilization and economic impact of Parkinson's disease in Germany. Mov Disord 2002; 17, Suppl. 5: 142

Spottke EA, Reuther M, Berger K, Smala A, Athen O, Koehne-Volland R, Singer M, Szucs T, Oertel WH, Dodel RC. Gesundheitsbezogene Lebensqualitätsmessungen beim M. Parkinson – zum Einsatz von Profil- oder Indexinstrumenten. Akt Neurol 2001; 28: S96

Spottke EA, Reuter M, Machat O, Bornschein B, Campenhausen S, Berger K, Koehne-Volland RK, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel W. Cost of Illness and Its Predictors for Parkinson's Disease in Germany. Pharmacoeconomics. 2004

Spottke EA, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005: 817-36

Spottke EA, Reuter M, Smala A, Berger K, Athen O, Koehne-Volland R, Meyer D, Oertel WH, Dodel R. Assessing The Costs of Parkinson's Disease. Value in Health 2001; 4: 519-520

Spottke AE, Reuter M, Smala A, Berger K, Athen O, Koehne-Volland R, Meyer D, Oertel WH, Dodel RC. Assessing the quality of life in Parkinson's disease. Value in Health 2001; 4:417

Spottke A, Volkmann J, Dodel R et al. Quality of life and healthcare utilization in Patients with Parkinson's Disease treated with Deep Brain Stimulation of the Subthalamic Nucleus. Mov Dis 2000; 15 (suppl. 3): 61

Spottke EA, Volkmann J, Dodel RC, Smala AM, Sturm V, Gerstner A, Berger K, Freund HJ, Oertel WH. Lebensqualität und Kosten der Tiefenhirnstimulation des Nucl. Subthalamicus in der Behandlung von Patienten mit M. Parkinson. Akt Neurol 2000; S2: S177

Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, Gerstner A, Berger K, Hellwig D, Deuschl G, Freund HJ, Oertel WH, Dodel RC. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002; 249(6):759-66

Stausberg J, Nonnemacher M, Weiland D, Antony G, Neuhäuser M. Management of Data Quality - Development of a Computer-Mediated Guideline. In: Hasman A, Haux R, van der Lei J, De Clercq E, Roger France FH, eds. Ubiquity: Technologies for Better Health in Aging Societies. Amsterdam: IOS, 2006: 477-82

Stolze H, Klebe S, Baecker C, Zechlin C, Friege L, Deuschl G. Prevalence of gait disorders in hospitalized neurological patients. Mov Disord 2005; 20:89-94

Stolze H, Klebe S, Poepping M, Lorenz D, Herzog J, Hamel W, Schrader B, Raethjen J, Wenzelburger R, Mehdorn M, Deuschl G, Krack P. Effects of bilateral subthalamic nucleus stimulation on Parkinsonian gait. Neurology 2001; 57:144-146

Strate P, Spottke EA, Dodel RC, Reuther M, Schreiber W, Athen O, Koehne-Volland R, Krieg JC, Oertel WH. Body image in patients with Parkinson's disease and in patients with depression. J Neural Transm 2001; 108: 22

Tatsch K, Pogarell O, Koch W, Hahn K, Gasser T, Radau P. Standardisierte Auswertung von SPECT Untersuchungen des prä- und postsynaptischen dopaminergen Systems. Abstract: in 'Nuklearmedizin als Paradigma molekularer Bildgebung', Hrsg.: Brink I. et al. Blackwell, Berlin, 2002; S. 17-18

Tatsch K, Pogarell O, Koch W, Hahn K, Gasser T, Radau P. Standardized evaluation of DAT and D2 receptor studies. Abstract: J Nucl Med 2002; 43: 201P - 202P

Tronnier VM, Fogel W, Krause M, Bonsanto MM, Tronnier J, Heck A, Munkel K, Kunze S. High frequency stimulation of the basal ganglia for the treatment of movement disorders: current status and clinical results. Minim Invasive Neurosurg 2002. 45(2):91-6

Trottenberg T, Meissner W, Kabus C, Arnold G, Funk T, Einhaupl KM, Kupsch A. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001; 16:769-771

Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic stimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001; 70:557-559

Trottenberg T, Volkmann J, Deuschl G, Kuhn AA, Schneider GH, Muller J, Alesch F, Kupsch A. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005; 64:344-346

Voges J, Sturm V. Neurochirurgische Prinzipien der Implantation von Elektroden in den Nucleus subthalamicus. Akt Neurol 2000; 27 Suppl 1:40-47

Voges J, Volkmann J, Allert N, Lehrke R, Koulousakis A et al. Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson`s disease: Correlation of therapeutic effect with anatomical electrode position. J Neurosurg 2002; 96:269-79

Voges J, Waerzeggers Y, Maarouf M, Lehrke R, Koulousakis A, Lenartz D, Sturm V. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery-experiences from a single centre. J Neurol Neurosurg Psychiatry. 2006; 77:868-872

Volkmann J, Allert N, Voges J, Weiss PH, Freund H-J and Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced Parkinson's disease. Neurology 2001; 56:548-551

Volkmann J, Benecke R. Deep brain stimulation for dystonia: Patient selection and evaluation. Mov Disord 2002; 17 Suppl 3:112-115

Volkmann J, Fogel W, Krack P. Postoperatives neurologisches Managment bei Stimulation des Nucleus subthalamicus. Akt Neurol 2000; 27 Suppl 1:23-39

Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. Mov Disord 2002; 17 Suppl 3:181-187

Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord 2006; 29:284-289

von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15:473-90

Wächter T, Odin P, Spieker S, Rissling I, Oertel WH. Kompetenznetz Parkinson – Forschung und Praxis verbinden, Der Neurologe und Psychiater 2000, 1:30-32

Walbert T, Reese JP, Dodel R. Krankheitskosten neurologischer Erkrankungen in Deutschland. Nervenheilkunde 2007; 26: 260-268

Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance. Arch Neurol 2001; 58:1076-79

Wenzelburger R, Kopper F, Zhang BR, Witt K, Hamel W, Weinert D, Kuhtz-Buschbeck J, Golge M, Illert M, Deuschl G, Krack P. Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements. Mov Disord 2003 Oct;18(10):1162-9

Wenzelburger R, Raethjen J, Loffler K, Stolze H, Illert M, Deuschl G. Kinetic tremor in a reach-to-grasp movement in Parkinson's disease. Mov Disord 2000; 15:1084-1094

Wenzelburger R, Zhang B, Poepping M, Schrader B, Mueller D, Kopper F, Fietzek U, Mehdorn HM, Deuschl G, Krack P. Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the nucleus subthalamicus. Ann Neurol 2002; 52(2):240-3

Wenzelburger R, Zhang B, Pohle S, Klebe S, Lorenz D, Herzog J, Wilms H, Deuschl G, Krack P. Force overflow contributes to levodopa-induced dyskinesias in Parkinson's disease. Brain 2002; 125:871-9

Wihl G, Volkmann J, Allert N, Lehrke R, Sturm V, Freund HJ. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001; 16(3):572-5

Williams D, Kuhn A, Kupsch A, Tijssen M, Van Bruggen G, Speelman H, Hotton G, Yarrow K, Brown P. Behavioural cues are associated with modulations of synchronous oscillations in the human subthalamic nucleus. Brain 2003 (Sep);126:1975-85

Witt K, Kopper F, Deuschl G, Krack P. Subthalamic nucleus influences spatial orientation in extra-personal space. Mov Disord 2006; 21:354-361

Wüllner U, Abele M, Schmitz-Hübsch T, Wilhelm K, Deuschl G, Benecke R, Klockgether T. Probable Multiple System Atrophy in a German family. Journal of Neurology, Neurosurgery and Psychiatry 2004

Wüllner U, Franke S, Antony G, Eggert K. Genbank Parkinson-Krankheit Deutschland (GEPARD). Nervenheilkunde 2007; 26: 246-250

Wüllner U, Klockgether T. Inflammation in Parkinson's disease. Journal of Neurology 2003; Vol. 250, 35-38

Wüllner U, Klockgether T. Klinik und Therapie der Multisystematrophie. Deutsches Ärzteblatt 2003; 7, 408-415

Wüllner U, Kölsch H, Linnebank M. Methylenetetrahydrofolate reductase in Parkinson's disease. Ann Neurol 2005; 58:972-973

Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K on behalf of the CNP. Features of probable Multiple System Atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicenter registry of the German Competence Network on Parkinson’s disease. J Neural Transm 2007

Wüllner U, Schmitz-Hübsch T, Antony G, Fimmers R, Spottke A, Oertel WH, Deuschl G, Eggert K on behalf of the CNP. Non-motor symptoms in Parkinson’s disease – a cross sectional analysis of 3414 patients enrolled in the German Network on Parkinson’s disease. Eur J Neurol 2007

Zhu XL, Hamel W, Schrader B, Weinert D, Hedderich J, Herzog J, Volkmann J, Deuschl G, Muller D, Mehdorn HM. Magnetic resonance imaging-based morphometry and landmark correlation of basal ganglia nuclei. Acta Neurochir (Wien) 2002; 144(10):959-69; discussion 968-9

Zimprich A, Asmus F, Leitner P, Castro M, Bereznai B, Homann N, Ott E, Rutgers AW, Wieditz G, Trenkwalder C, Gasser T. Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 2003; 4: 219-220

Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kachergus J, Calne D. B., Stoessl J, Uitti R. J., Pfeiffer R. F., Trenkwalder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T. The PARK8-locus in autosomal-dominant parkinsonism: confirmation of linkage and further delineation of the disease containing interval. Am J Hum Genet. Am J Hum Genet 2004 Jan; 74(1): 11-19

Zylka-Menhorn V. Kompetenznetzwerke: Eine Struktur gewinnt allmählich Inhalte. Deutsches Ärzteblatt 2002, 99, 1-2:A-24

 

 © Kompetenznetz Parkinson 2001 - 2011

 @ webmaster